饾悢饾惀饾惌饾惃饾惁饾悽饾惈饾悽饾惉 饾悆饾惈饾惍饾悹 饾悓饾悮饾惈饾悿饾悶饾惌 饾悊饾惈饾惃饾惏饾惌饾悺 Innovations in Rare Disease Biologics
The Ultomiris Drug Market is experiencing significant growth due to the increasing prevalence of rare autoimmune and hematologic disorders, rising awareness about complement-mediated diseases, and advancements in biologic therapies. Ultomiris (ravulizumab), a long-acting complement C5 inhibitor, has emerged as a breakthrough treatment for several life-threatening conditions, driving...
0 Commentarios 0 Acciones 293 Views